13 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
China Pharmaceutical University
Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
Federal University of Minas Gerais
In silico identification and biochemical characterization of novel inhibitors of NQO1.
University of Manchester
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
University of Manchester and Manchester Cancer Research Center
Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.
University of Manchester and Manchester Cancer Research Center
Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
University of Manchester
Recent advances of quinones as a privileged structure in drug discovery.
Jinan Second People'S Hospital
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
University of Manchester
Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.
China Pharmaceutical University
Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities.
Nantong University
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
China Pharmaceutical University
